Baker Ellis Asset Management’s Cardiff Oncology CRDF Stock Holding History

Baker Ellis Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26K	Hold	20,000	–	–	﹤0.01%	265
2026 Q1	$32.4K	Hold	20,000	–	–	﹤0.01%	254
2025 Q4	$56.2K	Hold	20,000	–	–	0.01%	260
2025 Q3	$41.2K	Hold	20,000	–	–	0.01%	249
2025 Q2	$63K	Hold	20,000	–	–	0.01%	215
2025 Q1	$62.8K	Hold	20,000	–	–	0.01%	219
2024 Q4	$86.8K	Hold	20,000	–	–	0.01%	212
2024 Q3	$53.4K	Buy	+20,000	New	+$47.2K	0.01%	224

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Baker Ellis Asset Management's CRDF Position: Q2 2026 in Review

Baker Ellis Asset Management held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 20,000 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #265.

Baker Ellis Asset Management first reported a position in CRDF in Q3 2024 and has held it in 8 quarters since. The position peaked at $86.8K in Q4 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Baker Ellis Asset Management held 20,000 shares of Cardiff Oncology worth $26K as of Q2 2026.
Baker Ellis Asset Management left its Cardiff Oncology share count unchanged in Q2 2026.
Cardiff Oncology made up ﹤0.01% of Baker Ellis Asset Management's portfolio in Q2 2026, its #265 holding.
Baker Ellis Asset Management first reported a position in Cardiff Oncology in Q3 2024 and has held it in 8 quarters since.
Baker Ellis Asset Management's Cardiff Oncology position peaked at $86.8K in Q4 2024.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Baker Ellis Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.